Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645]
Corresponding Author of This Article
Stefano Colagrande, MD, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Largo Brambilla 3, I-50134 Florence, Italy. stefano.colagrande@unifi.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 14, 2016; 22(34): 7645-7659 Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Table 1 Variables included in the most widely used hepatocellular carcinoma staging systems
Staging system
Ascites
Tumor burden
Albumin
Bilirubin
INR
HE
AFP
PVT
EHS
PS
ALP
Okuda
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
CLIP
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
BCLC
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
GRETCH
No
No
No
Yes
No
No
Yes
Yes
No
Yes
Yes
TNM 7th edition
No
Yes
No
No
No
No
No
Yes
Yes
No
No
Table 2 Results of studies with molecular targeted therapies as first line in advanced hepatocellular carcinoma
Treatment
Trial
OS
TTP
Ref.
Sorafenib
Phase III vs placebo
10.7 mo vs 7.9 mo, P < 0.001;
5.5 mo vs 2.8 mo, P < 0.001
[10]
(SHARP)
HR = 0.69; 95%CI: 0.55-0.87
Sorafenib
Phase III vs placebo
6.5 mo vs 4.2 mo, P = 0.014;
2.8 mo vs 1.4 mo, P = 0.0005;
[11]
(Asia-Pacific)
HR = 0.68; 95%CI: 0.50-0.93
HR = 0.57; 95%CI: 0.42-0.79
Sunitinib
Phase III vs sorafenib
7.9 mo vs 10.2 mo, P = 0.0019; HR = 1.30; 95%CI: 1.13-1.50
4.1 mo vs 3.8 mo, one-sided P = 0.8312;
[31]
(SUN)
two-sided P = 0.3082; HR = 1.13
Brivanib
Phase III vs sorafenib
9.5 mo vs 9.9 mo, P = 0.3116;
4.2 mo vs 4.1 mo, P = 0.853;
[32]
(BRISK-FL)
HR = 1.07; 95%CI: 0.94-1.23
HR = 1.01; 95%CI: 0.88-1.16
Linifanib
Phase III vs sorafenib
9.1 mo vs 9.8 mo, P = NS;
5.4 mo vs 4.0 mo, P = 0.001;
[33]
HR = 1.05; 95%CI: 0.90-1.22
HR = 0.759; 95%CI: 0.64-0.895
Erlotinib
Phase III erlotinib plus sorafenib and eorafenib plus placebo (SEARCH)
9.5 mo vs 8.5 mo, P = 0.408;
3.2 mo vs 4.0 mo, P = NS;
[36]
HR = 0.929
HR = 1.135; P = 0.18
Table 3 Results of studies with molecular targeted therapies as second line in advanced hepatocellular carcinoma
Treatment
Trial
OS
TTP/PFS
Ref.
Brivanib
Brivanib vs placebo (BRISK-PS)
9.4 mo vs 8.2 mo, P = 0.3307;
4.2 mo vs 2.7 mo, P < 0.001;
[42]
HR = 0.89; 95%CI: 0.69-1.15
HR = 0.56; 95%CI: 0.42-0.76
Everolimus
Everolimus vs placebo (EVOLVE-1)
7.6 mo vs 7.3 mo, P = 0.68;
3.0 mo vs 2.6 mo, P = 0.01;
[44]
HR = 1.05; 95%CI: 0.86-1.27
HR = 0.93; 95%CI: 0.75-1.15
Ramucirumab
Ramucirumab vs placebo (REACH)
9.2 mo vs 7.6 mo, P = 0.14;
2.8 mo vs 2.1 mo, P < 0.0001;
[45]
HR = 0.87; 95%CI: 0.72-1.05
HR = 0.63; 95%CI: 0.52-0.75
Table 4 Principal ongoing studies in advanced hepatocellular carcinoma with new molecular targeted therapies
Study
Drug
Status
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (e7080) vs sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma
Lenvatinib vs sorafenib
Active, not recruiting
Study of regorafenib after sorafenib in patients with hepatocellular carcinoma (RESORCE)
Regorafenib vs placebo
Recruiting
A study of dovitinib vs sorafenib in adult patients with hepatocellular carcinoma as a first line treatment
Dovitinib vs sorafenib
Completed (phase 2)
A study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Nivolumab vs sorafenib
Recruiting
Table 5 Assessment of target lesion response: Conventional Response Evaluation Criteria in Solid Tumors and modified Response Evaluation Criteria in Solid Tumors assessment for hepatocellular carcinoma following the American Association for the Study of Liver Diseases-Journal of the National Cancer Institute guideline
RECIST
mRECIST
CR: Disappearance of all target lesions.
CR: Disappearance of any intratumoral arterial enhancement in all target lesions.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions.
PR: At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.
SD: Any cases that do not qualify for either partial response or progressive disease.
SD: Any cases that do not qualify for either partial response or progressive disease.
PD: An increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.
PD: An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started.
Citation: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659